Sugi Predict

Sugi Predict / Compounds / SCHEMBL1596970

SCHEMBL1596970

SCHEMBL1596970

CN(C)C(=O)c1n[nH]c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 7/20 0.64
▸ KDM4E B2RXH2 4/20 0.61
▸ YTHDC1 Q96MU7 1/20 0.61
▸ STAT3 P40763 1/20 0.61
▸ HIF1A Q16665 1/20 0.61
▸ TSHR P16473 1/20 0.58
▸ CDK2 P24941 2/20 0.54
▸ CCNA2 P20248 1/20 0.54
▸ CCNA1 P78396 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ HTT P42858 1/20 0.53
▸ CTNNB1 P35222 2/20 0.53
▸ WNT3A P56704 2/20 0.53
▸ IDO1 P14902 1/20 0.51
▸ CDC7 O00311 1/20 0.51
▸ JAK1 P23458 1/20 0.49
▸ MAP4K1 Q92918 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7462506 0.87 KDM4E (0.58) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL18212238 0.84 TSHR (0.67) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL218633 0.84 KDM4E (0.63) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL29781840 0.80 KDM4E (0.67) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL217086 0.80 KDM4E (0.67) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL16416873 0.80 FLT3 (0.55) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL7668372 0.80 KDM4E (0.66) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL31148407 0.80 KDM4E (0.66) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL16910325 0.79 CDC7 (0.48) FLT3KDM4EYTHDC1STAT3HIF1A
SCHEMBL4793201 0.79 JAK1 (0.46) FLT3KDM4EYTHDC1STAT3HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116744918-A HSD17B13 inhibitors and uses thereof FL2022-001公司 2023-09-12 — — CN disclosed
EP-3541817-B1 IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA BRISTOL MYERS SQUIBB CO (US) 2020-12-23 — — EP disclosed
WO-2018093968-A1 IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-24 — — WO disclosed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 — — US disclosed
EP-2890693-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS Respivert Limited (GB) 2015-07-08 — — EP disclosed
US-8901313-B2 6,5-heterocyclic propargylic alcohol compounds and uses therefor GENENTECH, INC. (US) 2014-12-02 — — US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 — — US disclosed
WO-2014033448-A1 PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS RESPIVERT LIMTED (GB) 2014-03-06 — — WO disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 — — US disclosed
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR GENENTECH, INC. (US) 2012-08-23 — — US disclosed
US-7919517-B2 Indazole derivatives KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-04-05 — — US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 — — US disclosed
US-20090082348-A1 INDAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-03-26 — — US disclosed
US-7470717-B2 Indazole derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-12-30 — — US disclosed
CN-100390149-C Indazole derivatives KYOWA HAKKO KOGYO KK (JP) 2008-05-28 — — CN disclosed
US-20070117856-A1 Indazole derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-24 — — US disclosed
US-20060281789-A1 Protein kinase inhibitors KYOWA HAKKO KOGYO CO., LTD (JP) 2006-12-14 — — US disclosed
CN-1777590-A Indazole derivatives KYOWA HAKKO KOGYO KK (JP) 2006-05-24 — — CN disclosed
EP-1652842-A1 INDAZOLE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-05-03 — — EP disclosed
EP-1650194-A1 PROTEIN KINASE INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281789-A1 Protein kinase inhibitors MAP3K20, MAP3K1, MAP3K19 FLT3 579/4885KDM4E 1355/4885YTHDC1 3509/4885
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 FLT3 312/4885KDM4E 1238/4885YTHDC1 4384/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 FLT3 312/4885KDM4E 1238/4885YTHDC1 4384/4885
US-20070117856-A1 Indazole derivatives IGF1R, NR0B2, ADRA2B FLT3 684/4885KDM4E 2972/4885YTHDC1 4089/4885
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR NFKB1, NFRKB, NFKBIA FLT3 3438/4885KDM4E 3644/4885YTHDC1 3705/4885
US-20090082348-A1 INDAZOLE DERIVATIVES IGF1R, NR0B2, ADRA2B FLT3 684/4885KDM4E 2972/4885YTHDC1 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.